Building on previous work showing the clinical potential of targeting Klk5 in Netherton syndrome (Furio et al., 2014, 2015), our work establishes KLK7 and ELA2 as promising targets for the treatment of Netherton syndrome patients through the activation of NRF2 and subsequent upregulation of SLPI. Here, SLPI is linked to Netherton syndrome.